Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of EMR alone versus EMR followed by photodynamic therapy for early Barrett's cancer
NL-OMON31690Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of 5-aminolevulinic acid in Barrett's esophagus and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Recurrence of severe dysplasia or cancer. Started Jun 2008; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON31690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31690.